Merck & Co's Keytruda Disappoints In Small-Cell Lung Cancer

Triple-Negative Breast Cancer The Next Big Therapeutic Opportunity?

Jan 07 2020

• By John Davis

In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.

Merck & Co. Inc.’s release of somewhat disappointing top-line final Phase III data from the KEYNOTE-604 study of Keytruda (pembrolizumab) in extensive-stage small-cell lung cancer (SCLC) has drawn attention to what may be one of the remaining major untapped markets for the anti-PD-1 immunotherapy.

In KEYNOTE-604, Keytruda was found to significantly improve progression-free survival (PFS) but not overall survival (OS) when combined with chemotherapy...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Sanofi/Orano Look To Next Steps After Phase II Radiotherapy Success

Oct 08 2025

• By Alaric DeArment

The companies announced positive Phase II results for AlphaMedix, a lead 212-based alpha emitter therapy for gastroenteropancreatic neuroendocrine tumors.

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

Oct 08 2025

• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

Oct 08 2025

• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

Oct 07 2025

• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.

Biomea Plans To Advance Menin Inhibitor In Two Type 2 Diabetes Subgroups

Oct 07 2025

• By Joseph Haas

With 52-week Phase II data, struggling Biomea said it would go forward in insulin-deficient type 2 diabetes patients and those who had not achieved HbA1c goals on GLP-1 therapy.